Re:Goldman Sachs questions whether curing patients is a sust...
by azernik on Friday April 13, 2018 @05:54AM
(#16828430)
The third case is:
- you control only a fraction of the ongoing-treatment market, and the windfall you could get as a monopolist in the short-lived cure market is worth losing out on that steady cash flow
- you control only a fraction of the ongoing-treatment market, and the windfall you could get as a monopolist in the short-lived cure market is worth losing out on that steady cash flow